159 related articles for article (PubMed ID: 35443743)
1. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.
Adnan Awad S; Brück O; Shanmuganathan N; Jarvinen T; Lähteenmäki H; Klievink J; Ibrahim H; Kytölä S; Koskenvesa P; Hughes TP; Branford S; Kankainen M; Mustjoki S
Blood Cancer J; 2022 Apr; 12(4):69. PubMed ID: 35443743
[No Abstract] [Full Text] [Related]
2. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
3. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
4. Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
Tiribelli M; Toffoletti E; Di Giusto S; Fanin R; Damiani D
Eur J Haematol; 2023 Mar; 110(3):330-331. PubMed ID: 36458956
[No Abstract] [Full Text] [Related]
5. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
6. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
[TBL] [Abstract][Full Text] [Related]
7. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
9. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
[TBL] [Abstract][Full Text] [Related]
11. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
13. Evidence of
Turhan AG; Hugues P; Sorel N; Desterke C; Bourhis JH; Bennaceur-Griscelli A; Chomel JC
Leuk Lymphoma; 2020 Jul; 61(7):1719-1723. PubMed ID: 32122205
[No Abstract] [Full Text] [Related]
14. Tyrosine kinase inhibitors induce alternative spliced BCR-ABL
Yuda J; Odawara J; Minami M; Muta T; Kohno K; Tanimoto K; Eto T; Shima T; Kikushige Y; Kato K; Takenaka K; Iwasaki H; Minami Y; Ohkawa Y; Akashi K; Miyamoto T
Cancer Sci; 2020 Jul; 111(7):2361-2373. PubMed ID: 32314454
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
[TBL] [Abstract][Full Text] [Related]
16. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
17. Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?
Bhreathnach Ú; Langabeer SE
Int J Lab Hematol; 2022 Apr; 44(2):e67-e68. PubMed ID: 34585520
[No Abstract] [Full Text] [Related]
18. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
19. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
20. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Giles FJ; Cortes J; Jones D; Bergstrom D; Kantarjian H; Freedman SJ
Blood; 2007 Jan; 109(2):500-2. PubMed ID: 16990603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]